niclosamide has been researched along with Breast Neoplasms in 17 studies
Niclosamide: An antihelmintic that is active against most tapeworms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p48)
niclosamide : A secondary carboxamide resulting from the formal condensation of the carboxy group of 5-chlorosalicylic acid with the amino group of 2-chloro-4-nitroaniline. It is an oral anthelmintic drug approved for use against tapeworm infections.
Breast Neoplasms: Tumors or cancer of the human BREAST.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Therefore, we aimed to evaluate the cytotoxic effects of palladium(II) complex which is formulated as [PdCl(terpy)](sac)2H2O and its combination with niclosamide which is an inhibitor of Wnt signaling pathway associated with breast cancer stem cells." | 7.81 | Addition of niclosamide to palladium(II) saccharinate complex of terpyridine results in enhanced cytotoxic activity inducing apoptosis on cancer stem cells of breast cancer. ( Ari, F; Aztopal, N; Cevatemre, B; Karakas, D; Ulukaya, E; Yilmaz, VT, 2015) |
| "Niclosamide (NIC) is an anthelmintic drug and has been repositioned as anticancer agent after revealing its anti-neoplastic activity." | 5.91 | Fortified anti-proliferative activity of niclosamide for breast cancer treatment: In-vitro and in-vivo assessment. ( Adam, FA; Bakr, AF; El-Sherbiny, IM; Ghoniem, MG; Mahmoud, MY; Mansour, A, 2023) |
| "The microenvironment of breast cancer comprises predominantly of adipocytes." | 5.51 | Niclosamide reverses adipocyte induced epithelial-mesenchymal transition in breast cancer cells via suppression of the interleukin-6/STAT3 signalling axis. ( Choi, J; Gyamfi, J; Lee, YH; Min, BS, 2019) |
| " These findings suggest a role of niclosamide or derivatives optimized for more favorable bioavailability not only in reversing lapatinib resistance but also in reducing metastatic potential during the treatment of human epidermal growth factor receptor 2-positive breast cancer." | 5.43 | Niclosamide inhibits epithelial-mesenchymal transition and tumor growth in lapatinib-resistant human epidermal growth factor receptor 2-positive breast cancer. ( Bockhorn, J; Chen, X; Liu, J; Liu, X; Mao, Y; Pegram, M; Shen, K; Wang, G; Ward, T, 2016) |
| "Triple-negative breast cancer (TNBC) is one of the most difficult breast cancers to treat because there is no targeted treatment, and conventional cytotoxic chemotherapy followed by adjuvant radiation therapy is the standard of care for patients with TNBC." | 5.43 | Niclosamide sensitizes triple-negative breast cancer cells to ionizing radiation in association with the inhibition of Wnt/β-catenin signaling. ( Chen, H; Ding, D; Gao, Y; Wang, J; Yin, L; Zhang, J; Zhang, X; Zhang, Y, 2016) |
| "The potency of niclosamide on breast cancer was assessed in vitro and in vivo." | 5.40 | The anthelmintic drug niclosamide induces apoptosis, impairs metastasis and reduces immunosuppressive cells in breast cancer model. ( Li, D; Liu, L; Song, X; Wang, N; Wei, Y; Xia, Y; Xiong, Y; Yan, Y; Ye, T; Yu, L; Zeng, J; Zhang, L; Zhu, Y, 2014) |
| "Niclosamide treatment produced reduced levels of LRP6 and β-catenin, which is a downstream Wnt/β-catenin signaling protein." | 5.40 | Effect of niclosamide on basal-like breast cancers. ( Arend, RC; Aristizabal, L; Buchsbaum, DJ; Conner, M; Forero-Torres, A; Grizzle, WE; Hidalgo, B; Li, Y; Lobuglio, AF; Londoño-Joshi, AI; Lu, W; Metge, BJ; Samant, RS, 2014) |
| "The primary cause of death from breast cancer is the progressive growth of tumors and resistance to conventional therapies." | 5.39 | Drug screening identifies niclosamide as an inhibitor of breast cancer stem-like cells. ( Chang, CC; Chao, TK; Lai, HC; Wang, YC; Yo, YT; Yu, MH, 2013) |
| " Therefore, we aimed to evaluate the cytotoxic effects of palladium(II) complex which is formulated as [PdCl(terpy)](sac)2H2O and its combination with niclosamide which is an inhibitor of Wnt signaling pathway associated with breast cancer stem cells." | 3.81 | Addition of niclosamide to palladium(II) saccharinate complex of terpyridine results in enhanced cytotoxic activity inducing apoptosis on cancer stem cells of breast cancer. ( Ari, F; Aztopal, N; Cevatemre, B; Karakas, D; Ulukaya, E; Yilmaz, VT, 2015) |
| "Niclosamide (NIC) is an anthelmintic drug and has been repositioned as anticancer agent after revealing its anti-neoplastic activity." | 1.91 | Fortified anti-proliferative activity of niclosamide for breast cancer treatment: In-vitro and in-vivo assessment. ( Adam, FA; Bakr, AF; El-Sherbiny, IM; Ghoniem, MG; Mahmoud, MY; Mansour, A, 2023) |
| "Niclosamide (NLM) has prominent antitumor activities on various kinds of cancer." | 1.56 | Preparation and in vitro antitumor effects on MDA-MB-231 cells of niclosamide nanocrystals stabilized by poloxamer188 and PBS. ( Fu, Q; Jin, X; Lv, H; Zhang, Z, 2020) |
| "The microenvironment of breast cancer comprises predominantly of adipocytes." | 1.51 | Niclosamide reverses adipocyte induced epithelial-mesenchymal transition in breast cancer cells via suppression of the interleukin-6/STAT3 signalling axis. ( Choi, J; Gyamfi, J; Lee, YH; Min, BS, 2019) |
| "Apart from stimulating breast cancer cell motility via intracellular S100A4, ATP enhanced the ability of breast cancer cells to transform fibroblasts into cancer-associated fibroblast (CAF)-like cells, which in turn secreted S100A4 to further promote cancer cell motility." | 1.48 | Extracellular ATP drives breast cancer cell migration and metastasis via S100A4 production by cancer cells and fibroblasts. ( Fang, WG; Geng, YH; Liu, Y; Tian, XX; Yang, H; Zhang, HQ; Zhou, YT, 2018) |
| " These findings suggest a role of niclosamide or derivatives optimized for more favorable bioavailability not only in reversing lapatinib resistance but also in reducing metastatic potential during the treatment of human epidermal growth factor receptor 2-positive breast cancer." | 1.43 | Niclosamide inhibits epithelial-mesenchymal transition and tumor growth in lapatinib-resistant human epidermal growth factor receptor 2-positive breast cancer. ( Bockhorn, J; Chen, X; Liu, J; Liu, X; Mao, Y; Pegram, M; Shen, K; Wang, G; Ward, T, 2016) |
| "Triple-negative breast cancer (TNBC) is one of the most difficult breast cancers to treat because there is no targeted treatment, and conventional cytotoxic chemotherapy followed by adjuvant radiation therapy is the standard of care for patients with TNBC." | 1.43 | Niclosamide sensitizes triple-negative breast cancer cells to ionizing radiation in association with the inhibition of Wnt/β-catenin signaling. ( Chen, H; Ding, D; Gao, Y; Wang, J; Yin, L; Zhang, J; Zhang, X; Zhang, Y, 2016) |
| "Lastly, PP inhibited the growth of breast cancer cells harbouring PI3K mutations." | 1.43 | Computational drugs repositioning identifies inhibitors of oncogenic PI3K/AKT/P70S6K-dependent pathways among FDA-approved compounds. ( Amoreo, CA; Aria, V; Avvedimento, VE; Bardelli, A; Bosotti, R; Cardone, L; Carrella, D; Ciolli, L; Dattilo, R; di Bernardo, D; Iezzi, M; Isacchi, A; Loreni, F; Manni, I; Mottolese, M; Mutarelli, M; Papaccio, F; Sirci, F; Tumaini, B, 2016) |
| "The potency of niclosamide on breast cancer was assessed in vitro and in vivo." | 1.40 | The anthelmintic drug niclosamide induces apoptosis, impairs metastasis and reduces immunosuppressive cells in breast cancer model. ( Li, D; Liu, L; Song, X; Wang, N; Wei, Y; Xia, Y; Xiong, Y; Yan, Y; Ye, T; Yu, L; Zeng, J; Zhang, L; Zhu, Y, 2014) |
| "Niclosamide treatment produced reduced levels of LRP6 and β-catenin, which is a downstream Wnt/β-catenin signaling protein." | 1.40 | Effect of niclosamide on basal-like breast cancers. ( Arend, RC; Aristizabal, L; Buchsbaum, DJ; Conner, M; Forero-Torres, A; Grizzle, WE; Hidalgo, B; Li, Y; Lobuglio, AF; Londoño-Joshi, AI; Lu, W; Metge, BJ; Samant, RS, 2014) |
| "The primary cause of death from breast cancer is the progressive growth of tumors and resistance to conventional therapies." | 1.39 | Drug screening identifies niclosamide as an inhibitor of breast cancer stem-like cells. ( Chang, CC; Chao, TK; Lai, HC; Wang, YC; Yo, YT; Yu, MH, 2013) |
| "In this study, we used CSC-like human breast cancer cells and their alternate subset non-CSCs to investigate how IL-6 regulates the conversion of non-CSCs to CSCs." | 1.39 | Role of the IL-6-JAK1-STAT3-Oct-4 pathway in the conversion of non-stem cancer cells into cancer stem-like cells. ( Kang, JW; Kim, BK; Kim, SY; Kwon, YT; Lee, YJ; Song, X; Yoo, YD, 2013) |
| "Experiments in both breast cancer cells and cell-free systems demonstrated that niclosamide possesses protonophoric activity in cells and in vitro." | 1.38 | Structure-activity analysis of niclosamide reveals potential role for cytoplasmic pH in control of mammalian target of rapamycin complex 1 (mTORC1) signaling. ( Alain, T; Andersen, RJ; Balgi, AD; Bidinosti, MA; Dalal, K; Diering, GH; Duong, F; Fonseca, BD; Forestieri, R; Gunaratnam, C; Nodwell, M; Numata, M; Orlowski, J; Rajadurai, CV; Roberge, M; Sonenberg, N; Tee, AR, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 12 (70.59) | 24.3611 |
| 2020's | 5 (29.41) | 2.80 |
| Authors | Studies |
|---|---|
| Lohiya, G | 1 |
| Katti, DS | 1 |
| Dey, P | 1 |
| Joshi, M | 1 |
| Mujawar, A | 1 |
| Malhotra, R | 2 |
| De, A | 2 |
| Mansour, A | 1 |
| Mahmoud, MY | 1 |
| Bakr, AF | 1 |
| Ghoniem, MG | 1 |
| Adam, FA | 1 |
| El-Sherbiny, IM | 1 |
| Fu, Q | 1 |
| Jin, X | 1 |
| Zhang, Z | 1 |
| Lv, H | 1 |
| Dimri, S | 1 |
| Shet, T | 1 |
| Mokal, S | 1 |
| Gupta, S | 1 |
| Liu, Y | 1 |
| Geng, YH | 1 |
| Yang, H | 2 |
| Zhou, YT | 1 |
| Zhang, HQ | 1 |
| Tian, XX | 1 |
| Fang, WG | 1 |
| Gyamfi, J | 1 |
| Lee, YH | 1 |
| Min, BS | 1 |
| Choi, J | 1 |
| Wang, YC | 1 |
| Chao, TK | 1 |
| Chang, CC | 1 |
| Yo, YT | 1 |
| Yu, MH | 1 |
| Lai, HC | 1 |
| Ye, T | 1 |
| Xiong, Y | 1 |
| Yan, Y | 1 |
| Xia, Y | 1 |
| Song, X | 2 |
| Liu, L | 1 |
| Li, D | 1 |
| Wang, N | 1 |
| Zhang, L | 1 |
| Zhu, Y | 1 |
| Zeng, J | 1 |
| Wei, Y | 1 |
| Yu, L | 1 |
| Londoño-Joshi, AI | 1 |
| Arend, RC | 1 |
| Aristizabal, L | 1 |
| Lu, W | 2 |
| Samant, RS | 1 |
| Metge, BJ | 1 |
| Hidalgo, B | 1 |
| Grizzle, WE | 1 |
| Conner, M | 1 |
| Forero-Torres, A | 1 |
| Lobuglio, AF | 1 |
| Li, Y | 2 |
| Buchsbaum, DJ | 1 |
| Karakas, D | 1 |
| Cevatemre, B | 1 |
| Aztopal, N | 1 |
| Ari, F | 1 |
| Yilmaz, VT | 1 |
| Ulukaya, E | 1 |
| Liu, J | 1 |
| Chen, X | 1 |
| Ward, T | 1 |
| Mao, Y | 1 |
| Bockhorn, J | 1 |
| Liu, X | 1 |
| Wang, G | 1 |
| Pegram, M | 1 |
| Shen, K | 1 |
| Yin, L | 1 |
| Gao, Y | 1 |
| Zhang, X | 1 |
| Wang, J | 1 |
| Ding, D | 1 |
| Zhang, Y | 1 |
| Zhang, J | 1 |
| Chen, H | 1 |
| Carrella, D | 1 |
| Manni, I | 1 |
| Tumaini, B | 1 |
| Dattilo, R | 1 |
| Papaccio, F | 1 |
| Mutarelli, M | 1 |
| Sirci, F | 1 |
| Amoreo, CA | 1 |
| Mottolese, M | 1 |
| Iezzi, M | 1 |
| Ciolli, L | 1 |
| Aria, V | 1 |
| Bosotti, R | 1 |
| Isacchi, A | 1 |
| Loreni, F | 1 |
| Bardelli, A | 1 |
| Avvedimento, VE | 1 |
| di Bernardo, D | 1 |
| Cardone, L | 1 |
| Lin, C | 1 |
| Roberts, MJ | 1 |
| Waud, WR | 1 |
| Piazza, GA | 1 |
| Fonseca, BD | 1 |
| Diering, GH | 1 |
| Bidinosti, MA | 1 |
| Dalal, K | 1 |
| Alain, T | 1 |
| Balgi, AD | 1 |
| Forestieri, R | 1 |
| Nodwell, M | 1 |
| Rajadurai, CV | 1 |
| Gunaratnam, C | 1 |
| Tee, AR | 1 |
| Duong, F | 1 |
| Andersen, RJ | 1 |
| Orlowski, J | 1 |
| Numata, M | 1 |
| Sonenberg, N | 1 |
| Roberge, M | 1 |
| Kim, SY | 1 |
| Kang, JW | 1 |
| Kim, BK | 1 |
| Yoo, YD | 1 |
| Kwon, YT | 1 |
| Lee, YJ | 1 |
17 other studies available for niclosamide and Breast Neoplasms
| Article | Year |
|---|---|
Mesoporous Silica Nanoparticle-Based Combination of Niclosamide and Doxorubicin: Effect of Treatment Regimens on Breast Cancer Subtypes.
Topics: Antineoplastic Agents; beta Catenin; Breast Neoplasms; Doxorubicin; Female; Humans; Nanoparticles; N | 2021 |
Direct knockdown of phospho-PTM targets mediated by TRIM21 can improve personalized treatment in breast cancer.
Topics: Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Humans; Niclosamide; Precisio | 2022 |
Fortified anti-proliferative activity of niclosamide for breast cancer treatment: In-vitro and in-vivo assessment.
Topics: Anthelmintics; Antineoplastic Agents; Breast Neoplasms; Female; Humans; MCF-7 Cells; Nanoparticles; | 2023 |
Preparation and in vitro antitumor effects on MDA-MB-231 cells of niclosamide nanocrystals stabilized by poloxamer188 and PBS.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Cell Survival; Drug Compou | 2020 |
Noncanonical pS727 post translational modification dictates major STAT3 activation and downstream functions in breast cancer.
Topics: Animals; Anthelmintics; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Female; Humans; Mice | 2020 |
Extracellular ATP drives breast cancer cell migration and metastasis via S100A4 production by cancer cells and fibroblasts.
Topics: Adenosine Triphosphate; Animals; Apyrase; Breast Neoplasms; Cancer-Associated Fibroblasts; Cell Move | 2018 |
Niclosamide reverses adipocyte induced epithelial-mesenchymal transition in breast cancer cells via suppression of the interleukin-6/STAT3 signalling axis.
Topics: Adipocytes; Anthelmintics; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cel | 2019 |
Drug screening identifies niclosamide as an inhibitor of breast cancer stem-like cells.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Separat | 2013 |
The anthelmintic drug niclosamide induces apoptosis, impairs metastasis and reduces immunosuppressive cells in breast cancer model.
Topics: Animals; Anthelmintics; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell M | 2014 |
Effect of niclosamide on basal-like breast cancers.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protoco | 2014 |
Addition of niclosamide to palladium(II) saccharinate complex of terpyridine results in enhanced cytotoxic activity inducing apoptosis on cancer stem cells of breast cancer.
Topics: Apoptosis; Breast Neoplasms; Female; Humans; Neoplastic Stem Cells; Niclosamide; Palladium; Wnt Sign | 2015 |
Niclosamide inhibits epithelial-mesenchymal transition and tumor growth in lapatinib-resistant human epidermal growth factor receptor 2-positive breast cancer.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Dr | 2016 |
Niclosamide sensitizes triple-negative breast cancer cells to ionizing radiation in association with the inhibition of Wnt/β-catenin signaling.
Topics: Animals; Apoptosis; beta Catenin; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Female; Hu | 2016 |
Computational drugs repositioning identifies inhibitors of oncogenic PI3K/AKT/P70S6K-dependent pathways among FDA-approved compounds.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Carcinogenesis; Cell Line, Tumor; Computational Bi | 2016 |
Niclosamide suppresses cancer cell growth by inducing Wnt co-receptor LRP6 degradation and inhibiting the Wnt/β-catenin pathway.
Topics: Adaptor Proteins, Signal Transducing; Apoptosis; beta Catenin; Breast Neoplasms; Cell Line, Tumor; C | 2011 |
Structure-activity analysis of niclosamide reveals potential role for cytoplasmic pH in control of mammalian target of rapamycin complex 1 (mTORC1) signaling.
Topics: Animals; Antinematodal Agents; Breast Neoplasms; Cell Line; Cell Line, Tumor; Drug Screening Assays, | 2012 |
Role of the IL-6-JAK1-STAT3-Oct-4 pathway in the conversion of non-stem cancer cells into cancer stem-like cells.
Topics: Animals; Breast Neoplasms; Cell Line, Tumor; Cell Transformation, Neoplastic; Cytokines; Female; Gen | 2013 |